Molecular mechanism of lenvatinib resistance in hepatocellular carcinoma
Hepatocellular carcinoma is the most common malignancy of the liver and poses serious health burdens on China and the whole world.However,most patients with hepatocellular carcinoma are already in the advanced stage at the time of diagnosis,with fewer opportunities for surgery and limited treatment options.In recent years,the advances in molecular targeted therapies have brought new hope for patients with advanced hepatocellular carcinoma.Among these therapies,lenvatinib is the second first-line drug after sorafenib approved by the US Food and Drug Administration for the treatment of advanced hepatocellular carcinoma,and it has attracted widespread attention for its powerful anti-tumor properties.However,the efficacy of lenvatinib is severely limited by its drug resistance.This article reviews the research advances in the molecular mechanisms of lenvatinib resistance in hepatocellular carcinoma and discusses possible ways to improve the efficacy of lenvatinib,so as to improve its efficacy.
国家科技期刊平台
NSTL
万方数据
